For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Were the redundancy costs associated with the headcount reduction fully booked in the first half of the year? A: Yes, the restructuring costs of 168,000 were fully booked in the first half of the year. (Dara, CFO)
Q: How long is the 2.6 million of inventory expected to last? A: The inventory, which includes a mix of different devices, is expected to last over a 12-month timeframe. (Dara, CFO)
Q: Can you provide updates on the AI partnership with Care AI and Artisite? A: We are enabling health systems to choose any virtual care providers and leverage our API to deliver the virtual care experience through the OneView platform. We have validated Caregility and Teladoc, and are currently working with Care AI and Artisite based on customer requests. (James, CEO)
Q: Is the reduction in workforce signaling that OpEx has now peaked? A: Yes, we expect to see the benefits of the restructuring in the second half of the year, indicating that OpEx has peaked. (Dara, CFO)
Q: How confident are you in the alignment of incentives with the Baxter partnership? A: We believe the alignment is good, with incentives structured to ensure Baxter reps need to sell OneView products to achieve their variable compensation. (James, CEO)